Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2018
At a glance
- Drugs Sirolimus (Primary)
- Indications Tuberous sclerosis
- Focus Therapeutic Use
- Sponsors Aucta Pharmaceuticals
- 30 Apr 2018 Planned End Date changed from 1 Sep 2018 to 1 Jan 2019.
- 30 Apr 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Oct 2018.
- 30 Apr 2018 Status changed from not yet recruiting to recruiting.